Treatment for High-Risk HPV

There are over 100 types of human papillomavirus (HPV). Some of these are high-risk types that can lead to the development of cancer or precancer. There are treatments available for the health problems that can potentially develop from high-risk HPV types.
Which HPV Types Are High-Risk?

Each HPV is assigned a number. The types of HPV that are considered to be high-risk (cancer-causing) include:

    HPV-16
    HPV-18
    HPV-31
    HPV-33
    HPV-35
    HPV-39
    HPV-45
    HPV-51
    HPV-52
    HPV-56
    HPV-58
    HPV-59

These and other high-risk HPV types can potentially cause cancer of the cervix, vagina, vulva, penis, anus, and oropharynx. The most dangerous high-risk HPV types are HPV-16 and HPV-18. These two types of HPV cause approximately 70% of all cervical cancer cases. Visit full article  https://hpvhub.com/treatment-for-high-risk-hpv/

AHCC: A Natural Solution to HPV

Human papillomavirus (HPV) is a common virus that has been linked to several types of cancers. According to the CDC (1), about 80 million Americans are currently infected by some strain of the HPV virus. Despite the high prevalence rates, there is no known cure for the infection.

Researchers have identified over 100 subtypes of HPV virus in humans. In general, human papillomaviruses can be grouped into two groups: low-risk infections and high-risk infections. While in the majority of cases HPV infections are naturally suppressed within about two years, some high-risk subtypes can linger for more extended periods, leading to more serious complications such as genital warts and cervical cancer (2). Read more at https://hpvhub.com/ahcc-a-natural-solution-to-hpv/

A Single-Dose HPV Vaccine May Be Effective

With the supply of HPV vaccines dwindling, doctors and researchers are concerned about what this means for the spread of the disease. According to recent projections, there won’t be a sufficient number of HPV vaccine doses available to meet global demand until at least 2024. However, new research may provide a possible solution to the HPV vaccine shortage.

In an OBGYN News article published on May 29, 2019, follow-up results from major phase 3 randomized controlled trials of bivalent HPV vaccine in Costa Rica and quadrivalent vaccine in India were shared. These trials deliver promising evidence that a single HPV dose could provide protection against infection for 11 years or more. Since children who receive the vaccine at the recommended age currently receive two doses, this could potentially double the existing supply. Visit for more info: https://hpvhub.com/a-single-dose-hpv-vaccine-may-be-effective/